Conference Track

Lung Cancer

Source: CCO Independent Conference Coverage of the 2007 American Society of Clinical Oncology Annual Meeting*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Treatment Guided by ERCC1 and RRM1 Expression May Improve Response and Survival Outcomes in Patients With Advanced-Stage NSCLC
Docetaxel Therapy Administered Immediately After Gemcitabine/Carboplatin May Delay Disease Progression Without Added Toxicity Risk in Advanced-Stage NSCLC
Gefitinib Survival Outcome Not Inferior to Docetaxel in Patients With Advanced/Metastatic or Recurrent NSCLC
Preoperative Induction Chemotherapy Safe and Well Tolerated in Early-Stage NSCLC
Neoadjuvant Chemotherapy May Provide Clinical Benefit in Patients With NSCLC
Consolidation Docetaxel After Chemoradiation Demonstrated No Survival Benefit and Increased Toxicity in Patients With Unresectable Stage III NSCLC
Addition of Bevacizumab to Gemcitabine/Cisplatin Improves Response and Progression-Free Survival in Advanced or Recurrent NSCLC Patients
Cetuximab Increased Survival and Overall Response Rates When Used in Combination With Gemcitabine/Platinum-Based Chemotherapy in NSCLC Patients
Gene Expression Profiling Possibly Effective in Predicting Differential Response to Cisplatin and Pemetrexed in NSCLC
Gefitinib as Maintenance Therapy After Chemoradiation and Docetaxel Treatment May Negatively Impact Survival in Patients With NSCLC
Combination Irinotecan/Carboplatin Superior to Etoposide/Carboplatin in Small-Cell Lung Cancer With Extensive Disease
Single Nucleotide Polymorphisms May Account for Increased Toxicity From Irinotecan/Cisplatin Therapy in Patients With Small-Cell Lung Cancer With Extensive Disease
Adding Bevacizumab to Chemotherapy Does Not Improve Survival in Elderly Patients With NSCLC
Combination Therapy With Bevacizumab, Etoposide, and Cisplatin Active in Small-Cell Lung Cancer, Extensive Disease
Prophylactic Cranial Irradiation Decreases Risk for Brain Metastases and Death in Patients With Extensive-Disease Small-Cell Lung Cancer

Expert Analysis

Lung Cancer

Faculty:
David S. Ettinger, MD David R. Gandara, MD Corey J. Langer, MD

Moderator:
Barbara J. Gitlitz, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss the use of pharmacogenomic profiling in the selection of treatment for patients with non-small-cell lung cancer
Discuss the use of tyrosine kinase inhibitors in patients with advanced or recurrent non-small-cell lung cancer
Describe the use of cranial irradiation in the treatment of patients with small-cell lung cancer
Summarize recent data regarding the use of neoadjuvant chemotherapy in the treatment of patients with lung cancer

Topics covered include:

Prophylactic Cranial Irradiation in Patients With Extensive-Disease Small-Cell Lung Cancer
Pharmacogenomic Predictors of Response to Therapy
Chemoradiation Followed by Consolidation Therapy in Patients With Lung Cancer
Maintenance Gefitinib After Induction Chemoradiotherapy and Consolidation Docetaxel
Gefitinib vs Docetaxel in Japanese NSCLC Patients
Bevacizumab Added to Chemotherapy in Patients With Advanced-Stage NSCLC
Docetaxel Use Immediately After Chemotherapy in Lung Cancer
Preoperative Neoadjuvant Chemotherapy in Patients With Stage I-III NSCLC
Platinum-Based Combination Therapy in Extensive-Disease Small-Cell Lung Cancer
Cetuximab Plus Chemotherapy as First-Line Therapy in Advanced-Stage NSCLC

CME CREDIT INFORMATION

Release Date: 08/10/07

Expiration Date: 08/09/08

Physicians: maximum of 1.5 AMA PRA Category 1 Credit(s)™

Registered Nurses: 1.4 Nursing CE credits

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.